Tag: siponimod
First treatment for people with secondary progressive MS in Europe is approved
An important milestone for people with secondary progressive MS in Europe
Treatment licensed in US for people with active secondary progressive MS
FDA approves the drug Siponimod, to treat people with active secondary progressive MS
Siponimod offers hope for people with secondary progressive MS
A new, international clinical trial has shown that siponimod can slow progression in people with secondary progressive MS.
Research highlights of 2016
Professor Alan Thompson highlights some of 2016’s research discoveries in MS
What happened at ECTRIMS 2016?
Researchers and health professionals gather for the latest updates and research findings on treatment, care and management of MS